User menu

Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations.

Bibliographic reference Gallo, Paolo ; Van Wijmeersch, Bart ; ParadigMS Group ; Van Pesch, Vincent. Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations.. In: European Journal of Neurology, Vol. 22, no. 2, p. 14-21 (2015)
Permanent URL
  1. Kappos Ludwig, Freedman Mark S, Polman Chris H, Edan Gilles, Hartung Hans-Peter, Miller David H, Montalbán Xavier, Barkhof Frederik, Radü Ernst-Wilhelm, Metzig Carola, Bauer Lars, Lanius Vivian, Sandbrink Rupert, Pohl Christoph, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, 10.1016/s1474-4422(09)70237-6
  2. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial, 10.1016/s0140-6736(09)61259-9
  3. Jacobs Lawrence D., Beck Roy W., Simon Jack H., Kinkel R. Phillip, Brownscheidle Carol M., Murray Thomas J., Simonian Nancy A., Slasor Peter J., Sandrock Alfred W., Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, 10.1056/nejm200009283431301
  4. Miller, Neurol, 82, PL2.002 (2014)
  5. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., Reynolds R., Aloisi F., Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology, 10.1093/brain/awm038
  6. Leocani L, Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study, 10.1136/jnnp.2005.086280
  7. Petzold Axel, de Boer Johannes F, Schippling Sven, Vermersch Patrik, Kardon Randy, Green Ari, Calabresi Peter A, Polman Chris, Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis, 10.1016/s1474-4422(10)70168-x
  8. Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, Stubinski B, Stromillo ML, Montalban X, De Stefano N, Scoring treatment response in patients with relapsing multiple sclerosis, 10.1177/1352458512460605
  9. Sormani Maria Pia, Bruzzi Paolo, MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials, 10.1016/s1474-4422(13)70103-0
  10. Río J., Tintoré M., Sastre-Garriga J., Nos C., Castilló J., Tur C., Comabella M., Montalban X., Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response : Treatment switch in MS, 10.1111/j.1468-1331.2011.03648.x
  11. Caon C., Din M., Ching W., Tselis A., Lisak R., Khan O., Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis, 10.1111/j.1468-1331.2006.01273.x
  12. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E, Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis, 10.1177/1352458508096687
  13. Carrá A., Onaha P., Luetic G., Burgos M., Crespo E., Deri N., Halfon M., Jaacks G., López A., Sinay V., Vrech C., Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina, 10.1111/j.1468-1331.2008.02071.x
  14. Prosperini Luca, Borriello Giovanna, De Giglio Laura, Leonardi Laura, Barletta Valeria, Pozzilli Carlo, Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?, 10.1186/1471-2377-11-26
  15. Prosperini Luca, Giannì Costanza, Leonardi Laura, De Giglio Laura, Borriello Giovanna, Galgani Simonetta, Pozzilli Carlo, Gasperini Claudio, Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis, 10.1177/1352458511417481
  16. Belachew S., Phan-Ba R., Bartholomé E., Delvaux V., Hansen I., Calay P., Hafsi K. E., Moonen G., Tshibanda L., Vokaer M., Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis : Natalizumab improves disability in relapsing MS, 10.1111/j.1468-1331.2010.03112.x
  17. Putzki N., Kollia K., Woods S., Igwe E., Diener H. C., Limmroth V., Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis, 10.1111/j.1468-1331.2008.02519.x
  18. Oturai A. B., Koch-Henriksen N., Petersen T., Jensen P. E. H., Sellebjerg F., Sorensen P. S., Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study, 10.1111/j.1468-1331.2008.02517.x
  19. Spelman, Neurol, 82, P7.208 (2014)
  20. Butzkueven H., Kappos L., Pellegrini F., Trojano M., Wiendl H., Patel R. N., Zhang A., Hotermans C., Belachew S., , Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results, 10.1136/jnnp-2013-306936
  21. Bergvall Niklas, Makin Charles, Lahoz Raquel, Agashivala Neetu, Pradhan Ashish, Capkun Gorana, Petrilla Allison A., Karkare Swapna U., McGuiness Catherine Balderston, Korn Jonathan R., Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study, 10.1371/journal.pone.0088472
  22. Clerico Marinella, Schiavetti Irene, De Mercanti Stefania F., Piazza Federico, Gned Dario, Brescia Morra Vincenzo, Lanzillo Roberta, Ghezzi Angelo, Bianchi Anna, Salemi Giuseppe, Realmuto Sabrina, Sola Patrizia, Vitetta Francesca, Cavalla Paola, Paolicelli Damiano, Trojano Maria, Sormani Maria Pia, Durelli Luca, Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab : Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study), 10.1001/jamaneurol.2014.1200